ACS expands lung cancer screening eligibility to ages 50-80 with 20+ pack-years Previous guideline was 55-74 with 30+ pack years

MD Anderson’s Lauren Averett Byers receives TAMEST O’Donnell Award

Lauren Averett Byers, professor of thoracic/head & neck medical oncology at the University of Texas MD Anderson Cancer Center, received the 2025 Edith and Peter O’Donnell Award in Medicine from the Texas Academy of Medicine, Engineering, Science and Technology. The award recognizes her fundamental discoveries and contributions to identifying novel therapeutic strategies for small cell lung cancer, which have paved the way for personalized treatments, even in the most highly recalcitrant cancers.

December 13, 2024

Vol.50 No.46

In Brief

Break Through Cancer launches the PoweRD 2 Cure ALK+ Lung Cancer TeamLab

Break Through Cancer has launched the PoweRD 2 Cure ALK+ Lung Cancer TeamLab, a collaboration among nine leading cancer research institutions, including Break Through Cancer’s five partner institutions: Dana-Farber Cancer Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Memorial Sloan Kettering Cancer Center, MIT’s Koch Institute for Integrative Cancer Research, and the University of Texas MD Anderson Cancer Center, as well as newly engaged collaborators from Mass General Brigham, Boston Children’s Hospital, the University of Colorado Cancer Center and Vanderbilt University Medical Center.

December 06, 2024

Vol.50 No.45

In Brief

Rural Appalachian lung cancer screening initiative expands screening access

UVA Cancer Center, Appalachian Community Cancer Alliance, and Buchanan General Hospital have teamed up to make getting screened for lung cancer easier for residents of rural Virginia and West Virginia.

December 06, 2024

Vol.50 No.45

Clinical Roundup

Home testing kits, coordinated outreach improve CRC screening rates

Colorectal cancer screening is an effective tool for catching the disease early when it’s most treatable, yet it is underutilized in patient populations who receive primary care at federally qualified health centers.

December 06, 2024

Vol.50 No.45

Clinical Roundup

Tecentriq + tiragolumab does not improve OS, updated phase III data finds

Genentech’s phase III SKYSCRAPER-01 study, evaluating tiragolumab combined with Tecentriq (atezolizumab) compared to Tecentriq alone for patients with PD-L1-high, locally advanced or metastatic non-small cell lung cancer, did not reach the primary endpoint of overall survival at the final analysis. The overall safety profile observed remained consistent with longer follow-up, and no new safety signals were identified. The detailed data will be presented at a medical meeting in 2025.

December 06, 2024

Vol.50 No.45